Targeting a disrupted circadian regulator to treat advanced prostate cancer
Official title: Targeting aberrant circadian regulator in advanced prostate cancer
Funded at University of California at Davis · NIH-10993125 · Data updated 2026-11-12
This study is looking at how a specific protein called Rev-erbα affects advanced prostate cancer that doesn't respond to usual treatments, and it will test a new way to block this protein to see if it can help slow down the cancer and improve patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | December 15, 2021 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $368,288 |
| NIH project number | 5R01CA259081-04 |
| Project ID | NIH-10993125 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those with metastatic castration-resistant prostate cancer.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
What this research studies
This research investigates the role of a circadian rhythm regulator, Rev-erbα, in advanced prostate cancer, particularly in cases resistant to current therapies. The study aims to understand how this regulator contributes to tumor growth and survival in metastatic castration-resistant prostate cancer (mCRPC). By using small molecule antagonists to inhibit Rev-erbα, the research seeks to determine the effectiveness and safety of this approach in treating aggressive forms of prostate cancer. Patients may be monitored for changes in tumor behavior and response to treatment.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer that is resistant to existing therapies.
How similar studies have gone: Previous research has shown promise in targeting circadian regulators in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Chen, Hongwu — University of California at Davis
- Study coordinator: Chen, Hongwu
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.